<DOC>
	<DOCNO>NCT00371488</DOCNO>
	<brief_summary>This two-part study ( Phase I/Phase II ) . Part I design find optimal ( best ) dose GW572016 trastuzumab give together , Part II design evaluate tumor response rate ( shrinkage lack growth ) patient receive lapatinib trastuzumab .</brief_summary>
	<brief_title>GW572016 Combined With Trastuzumab For The Treatment Of Previously Trastuzumab-Treated Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Inclusion criterion : Patients confirm breast cancer receive prior trastuzumab . Patients must adequate blood , liver , kidney function either fully active restrict perform strenuous activity . Female patient childbearing potential must willing abstain intercourse 2 week prior administration first dose study medication 28 day final dose study medication willing consistently correctly use acceptable method birth control . Exclusion criterion : Patients certain heart problem .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>ErbB2</keyword>
	<keyword>Stage IV breast cancer</keyword>
	<keyword>ErbB1</keyword>
	<keyword>breast cancer</keyword>
	<keyword>lapatinib</keyword>
	<keyword>Herceptin</keyword>
	<keyword>trastuzumab</keyword>
</DOC>